Value Beacon
Long/short equity

A Short Case For PDL Biopharma: Why The Company Is Worth Less Than $5 A Share

A short case for PDL Biopharma: Simple math to understand why PDLI is worth less than $5 a share

In this note I will attempt to explain why I believe PDL Biopharma (NYSE: PDLI) may have substantial downside risk, why investors may be choosing to ignore this risk, why it only takes simple math to understand the firm's current value, and the catalysts for rapid price discovery in the shares. In short, if I am correct, PDLI may be vulnerable to a 40% sell-off to $5 a share or less from its current price of $8.25.

A (Very) Brief History

PDL Biopharma is a pharmaceutical royalty company. The shares have been well covered in these pages over the past...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details